The cancer vaccine field has seen its share of late-stage disappointments and outright flops, but a number of hopefuls are lining up to present new research backing their experimental shots at this year's upcoming American Society of Clinical Oncology Annual Meeting in Chicago.
The discovery of a molecule that coaxes cells to self-destruct may provide a novel way to treat immune disorders and inflammation, according to a new study.
A response between monocyte-derived dendritic cells and cancer has dealt a setback when it comes to fighting the disease with vaccines.
The Infectious Disease Research Institute and Medicago plan to remove the 'ouch' from vaccine administration. The pair is working on delivering virus-like particles through a device that uses pain-free microneedles.
They exist. Researchers from Newcastle University in the U.K. and colleagues have spotted a new type of white blood cell that, in response to some kind of external source, can activate a killing immune response in the body.
Vaccibody's lead therapeutic DNA vaccine, developed for the treatment of precancerous changes in the cervix caused by human papillomavirus (HPV) infection, is expected to move into the clinic in late 2013 once funding is in place, the company CEO Ole Henrik Brekke told FierceVaccines at BIO 2012.
Creating vaccines that bind to a damaged cell-recognition molecule called Clec9A could trick dendritic cells into thinking they have encountered a damaged cell and help to launch an immune response.
Today, we're one small but significant step closer to figuring out how to get certain cells to fight back against HIV infection. Specifically, scientists with the NYU Langone Medical Center and